Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Tumor-Agnostic 1 Lymphoid 1

Conditions

Interventions

Paclitaxel 58 Gemcitabine 51 Carboplatin 51 Surveys and Questionnaires 48 Docetaxel 38 Bevacizumab 37 pembrolizumab 33 Nivolumab 30 Cisplatin 28 Fluorouracil 24 Irinotecan 23 Capecitabine 23 Erlotinib Hydrochloride 22 Sorafenib 20 Leucovorin 19 Afatinib 19 Radiotherapy 18 Pemetrexed 18 Oxaliplatin 17 Trastuzumab 16 regorafenib 15 Ipilimumab 15 Blood Specimen Collection 14 Albumin-Bound Paclitaxel 14 130-nm albumin-bound paclitaxel 14 olaparib 13 Interviews as Topic 13 Cetuximab 13 atezolizumab 12 Sunitinib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × eryaspase × Tumor-Agnostic × Clear all

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed

512 enrolled 19 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡